Seer (SEER) Net Margin % : -481.25% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Seer Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Seer's Net Income for the three months ended in Mar. 2025 was $-19.95 Mil. Seer's Revenue for the three months ended in Mar. 2025 was $4.15 Mil. Therefore, Seer's net margin for the quarter that ended in Mar. 2025 was -481.25%.

The historical rank and industry rank for Seer's Net Margin % or its related term are showing as below:

SEER' s Net Margin % Range Over the Past 10 Years
Min: -27651.72 Med: -633.07 Max: -568.28
Current: -570.1

SEER's Net Margin % is ranked worse than
71.21% of 983 companies
in the Biotechnology industry
Industry Median: -110.23 vs SEER: -570.10

Seer Net Margin % Historical Data

The historical data trend for Seer's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Net Margin % Chart

Seer Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

Get a 7-Day Free Trial

-1,113.06

-633.07

-568.28

-620.91

Seer Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Margin %	Get a 7-Day Free Trial															-682.48	-755.12	-541.05	-550.57	-481.25

Competitive Comparison of Seer's Net Margin %

For the Biotechnology subindustry, Seer's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seer's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Net Margin % distribution charts can be found below:

* The bar in red indicates where Seer's Net Margin % falls into.

Save Embed

;

Save Embed

;

Seer Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Seer's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-86.599	/	13.947
	=	-620.91 %

Seer's Net Margin for the quarter that ended in Mar. 2025 is calculated as

Net Margin	=	Net Income (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-19.948	/	4.145
	=	-481.25 %

Seer (NAS:SEER) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Seer Net Margin % Related Terms

Thank you for viewing the detailed overview of Seer's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Seer Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065

Website

https://www.seer.bio

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Executives

David R. Horn	officer: Chief Financial Officer	3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad	director, 10 percent owner, officer: CEO and Chair of the Board	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Dipchand Nishar	director	C/O LINKEDIN CORPORATION, 2029 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Elona Esq. Kogan	officer: General Counsel and Secretary	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas	officer: Chief Commercial Officer	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan	director, officer: President & COO	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani	director	C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz	director	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer	director	C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111